Alan J. Tackett

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy Federal Grant PI High Impact

IDeA National Resource for Quantitative Proteomics

UAMS primary UA Little Rock Hendrix College University of Arkansas

Also affiliated: Rutgers, The State University of New Jersey (2008); University of Rome Tor Vergata (2016); Arkansas Children's Hospital (2018–2023); Pennsylvania State University (2002); Johns Hopkins University (2009–2013); University of California, Los Angeles (2022); Vanderbilt University (2002–2014); University of Arkansas Medical Center (2015–2020); Johns Hopkins Medicine (2009); Cancer Institute (WIA) (2025); Lebanon VA Medical Center (2013); Abterra Biosciences (United States) (2018–2020); Central Arkansas Veterans Healthcare System (2016–2018); Advanced Projects Research Incorporated (United States) (2019); Cancer Research Center (2024); Winthrop Rockefeller Foundation (2019–2026); Arkansas Children's Nutrition Center (2018–2020); Arkansas Department of Agriculture (2011–2023); Penn State Milton S. Hershey Medical Center (2013); Rockefeller University (2003–2016)

Faculty Researcher

Biochemistry & Molecular Biology, College of Medicine

51 h-index 284 pubs 10,610 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Alan J. Tackett's research focuses on the molecular mechanisms underlying cancer development and potential therapeutic strategies. He leads a research group and holds a Principal Investigator role on multiple federal grants totaling over $2.8 million, including significant funding from the NIH/National Institute of General Medical Sciences for the IDeA National Resource for Quantitative Proteomics. His work investigates how cellular processes, such as phase separation and chromatin looping, contribute to cancer, as evidenced by publications on aberrant chromatin looping and its role in cancer development. Additionally, Tackett explores novel therapeutic approaches, including the development of PROTAC degraders targeting specific oncogenic proteins like NSD3 and WDR5, as well as investigating combinations of immunotherapies and MAPK inhibitors for enhanced anti-tumor immunity.

His scholarship is characterized by a strong publication record, with over 284 publications and more than 10,000 citations, reflected in his h-index of 51 and designation as a highly cited researcher. Tackett's research utilizes advanced proteomic techniques, including mass spectrometry, to identify and characterize therapeutic targets. His recent publications also delve into the regulatory roles of specific proteins and complexes, such as ZMYND11 and TNRC18, in gene silencing, retrotransposon activity, and leukemogenesis. Collaborations with researchers at the University of Arkansas for Medical Sciences, including Samuel G. Mackintosh, Aaron J. Storey, Stephanie D. Byrum, and Nathan L. Avaritt, underscore the network of his research endeavors.

Metrics

h-index: 51
Publications: 284
Citations: 10,610

Selected Publications

Repurposing Monensin and Its Derivatives as Immune-Modulatory Candidates for Metastatic Breast Cancer (Abstract ID: 231537) (2026)

DOI OpenAlex
Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection (2026)

DOI OpenAlex
Dynamic global acetylation remodeling during the yeast heat shock response (2026)

Genome biology 1 citation DOI OpenAlex
Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification (2025)

Nature Structural & Molecular Biology 3 citations DOI OpenAlex
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)

ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG (2025)

Oncogene 7 citations DOI OpenAlex
BAHCC1 binds H4K20me1 to facilitate the MCM complex loading and DNA replication (2025)

Nature Communications 3 citations DOI OpenAlex
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis (2025)

Journal of Thrombosis and Haemostasis 2 citations DOI OpenAlex
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025)

iScience 1 citation DOI OpenAlex
The phenylalanine-and-glycine repeats of NUP98 oncofusions form condensates that selectively partition transcriptional coactivators (2025)

Molecular Cell 25 citations DOI OpenAlex
Staphylococcus aureus Proteins Implicated in the Reduced Virulence of sarA and sarA/agr Mutants in Osteomyelitis (2025)

Microorganisms 6 citations DOI OpenAlex
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024)

RSC Medicinal Chemistry 1 citation DOI OpenAlex
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)

Chemistry & Biodiversity 1 citation DOI OpenAlex
TNRC18 engages H3K9me3 to mediate silencing of endogenous retrotransposons (2023)

Nature 69 citations DOI OpenAlex
Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma (2023)

Molecular Immunology 5 citations DOI OpenAlex

View all publications on OpenAlex →

ARA Academy 2021 ARA Fellow

Dr. Tackett leads a translational research team examining immunotherapy resistance in cancer treatment, specifically understanding why some patients show limited response to immunotherapies. His work combines research with clinical collaboration among oncologists, surgeons, and pathologists to develop new therapies for metastatic melanoma treatment.

Policy Impact

Advancing cancer immunotherapy research at the UAMS Rockefeller Cancer Institute, attracting federal funding and clinical collaborations that benefit cancer patients statewide.